Quick Answer
Aptose Biosciences Inc. reported Total Assets of $10.01 million for the year ending 2025.
- Aptose Biosciences Inc. showed a decrease of -1.1% in Total Assets from 2024 to 2025.
- This data is from Aptose Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $19.72 million | Q2 2019: $38.19 million | Q3 2019: $32.46 million | Q1 2020: $92.56 million | Q2 2020: $85.32 million | Q3 2020: $135.26 million | Q1 2021: $115.20 million | Q2 2021: $106.21 million | Q3 2021: $97.20 million | Q1 2022: $72.60 million | Q2 2022: $64.81 million | Q3 2022: $57.05 million | Q1 2023: $39.33 million | Q2 2023: $26.58 million | Q3 2023: $20.88 million | Q1 2024: $12.80 million | Q2 2024: $10.95 million | Q3 2024: $10.93 million | Q1 2025: $7.47 million | Q2 2025: $5.59 million | Q3 2025: $6.34 million.
- Over the full 9 years of available data (2017 to 2025), Aptose Biosciences Inc.'s Total Assets has declined by 16.3%.
- Historical annual values: Fiscal year 2025: $10.01 million | Fiscal year 2024: $10.13 million | Fiscal year 2023: $12.99 million | Fiscal year 2022: $51.03 million | Fiscal year 2021: $82.53 million | Fiscal year 2020: $126.26 million | Fiscal year 2019: $100.48 million | Fiscal year 2018: $16.87 million | Fiscal year 2017: $11.97 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: